GlobeNewsWire
27 Mar 2026, 13:00 UTC · 31w ago
Verdict
Headline takes no side. We score BW −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 99% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) rejecting the New Drug Application for Disc Medicine's primary drug candidate, bitopertin.
More negative than 99% of claims this week
The FDA concluded that clinical trials for bitopertin failed to show evidence of association between percent change in PPIX and sunlight exposure-based endpoints for EPP treatment.
Continue reading
5 related stories
Search tags
More negative than 98% of claims this week
The Portnoy Law Firm has initiated an investigation into possible securities fraud and may file a class action against Disc Medicine.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company is the subject of a class action lawsuit notification.
More negative than 99% of ticker scores this week
The company is the subject of a class action lawsuit notification.
More negative than 99% of ticker scores this week
Company is facing a securities fraud investigation and a major FDA rejection of its primary drug candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
2h ago
−70.5%
Price agrees with the score
$4.27 vs $14.46 close before publication (Mar 26) · not market-adjusted
BW chart →
